.

Make Better Decisions

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Obtain formulation and manufacturing information

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Accenture
Chubb
Queensland Health
McKesson
Merck
Moodys
Johnson and Johnson
Argus Health
Mallinckrodt
Teva

Generated: January 20, 2018

DrugPatentWatch Database Preview

Patents Expiring in May 2023

« Back to Dashboard

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Shire Dev LlcMYDAYISamphetamine aspartate; amphetamine sulfate; dextroamphetamine saccharate; dextroamphetamine sulfateCAPSULE, EXTENDED RELEASE;ORAL022063-001Jun 20, 2017RXYesNo➤ Subscribe➤ SubscribeY
Shire Dev LlcMYDAYISamphetamine aspartate; amphetamine sulfate; dextroamphetamine saccharate; dextroamphetamine sulfateCAPSULE, EXTENDED RELEASE;ORAL022063-004Jun 20, 2017RXYesNo➤ Subscribe➤ SubscribeY
Shire Dev LlcMYDAYISamphetamine aspartate; amphetamine sulfate; dextroamphetamine saccharate; dextroamphetamine sulfateCAPSULE, EXTENDED RELEASE;ORAL022063-003Jun 20, 2017RXYesNo➤ Subscribe➤ SubscribeY
Shire Dev LlcMYDAYISamphetamine aspartate; amphetamine sulfate; dextroamphetamine saccharate; dextroamphetamine sulfateCAPSULE, EXTENDED RELEASE;ORAL022063-002Jun 20, 2017RXYesNo➤ Subscribe➤ SubscribeY
Novartis Pharms CorpPROMACTAeltrombopag olamineTABLET;ORAL022291-004Oct 20, 2011RXYesNo➤ Subscribe➤ SubscribeY
Novartis Pharms CorpPROMACTAeltrombopag olamineFOR SUSPENSION;ORAL207027-001Aug 24, 2015RXYesYes➤ Subscribe➤ SubscribeY
Novartis Pharms CorpPROMACTAeltrombopag olamineTABLET;ORAL022291-005Nov 16, 2012RXYesYes➤ Subscribe➤ SubscribeY
Novartis Pharms CorpPROMACTAeltrombopag olamineTABLET;ORAL022291-003Sep 8, 2009RXYesYes➤ Subscribe➤ SubscribeY
Novartis Pharms CorpPROMACTAeltrombopag olamineTABLET;ORAL022291-002Nov 20, 2008RXYesNo➤ Subscribe➤ SubscribeY
Novartis Pharms CorpPROMACTAeltrombopag olamineTABLET;ORAL022291-001Nov 20, 2008RXYesNo➤ Subscribe➤ SubscribeY
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Healthtrust
Colorcon
Federal Trade Commission
AstraZeneca
Fuji
Cerilliant
Teva
McKesson
Moodys
UBS

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2018 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot